An On-Demand pH-Sensitive Nanocluster for Cancer Treatment by Combining Photothermal Therapy and Chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sim, Taehoon | - |
dc.contributor.author | Lim, Chaemin | - |
dc.contributor.author | Hoang, Ngoc Ha | - |
dc.contributor.author | Shin, Yuseon | - |
dc.contributor.author | Kim, Jae Chang | - |
dc.contributor.author | Park, June Yong | - |
dc.contributor.author | Her, Jaewon | - |
dc.contributor.author | Lee, Eun Seong | - |
dc.contributor.author | Youn, Yu Seok | - |
dc.contributor.author | Oh, Kyung Taek | - |
dc.date.accessioned | 2022-01-20T01:45:05Z | - |
dc.date.available | 2022-01-20T01:45:05Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53916 | - |
dc.description.abstract | Combination therapy is considered to be a promising strategy for improving the therapeutic efficiency of cancer treatment. In this study, an on-demand pH-sensitive nanocluster (NC) system was prepared by the encapsulation of gold nanorods (AuNR) and doxorubicin (DOX) by a pH-sensitive polymer, poly(aspartic acid-graft-imidazole)-PEG, to enhance the therapeutic effect of chemotherapy and photothermal therapy. At pH 6.5, the NC systems formed aggregated structures and released higher drug amounts while sustaining a stable nano-assembly, structured with less systemic toxicity at pH 7.4. The NC could also increase antitumor efficacy as a result of improved accumulation and release of DOX from the NC system at pH(ex)and pH(en)with locally applied near-infrared light. Therefore, an NC system would be a potent strategy for on-demand combination treatment to target tumors with less systemic toxicity and an improved therapeutic effect. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | An On-Demand pH-Sensitive Nanocluster for Cancer Treatment by Combining Photothermal Therapy and Chemotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/pharmaceutics12090839 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, v.12, no.9, pp 1 - 14 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000580843100001 | - |
dc.identifier.scopusid | 2-s2.0-85093880876 | - |
dc.citation.endPage | 14 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | PHARMACEUTICS | - |
dc.citation.volume | 12 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | gold nanorod | - |
dc.subject.keywordAuthor | photothermal therapy | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | pH sensitive polymer | - |
dc.subject.keywordAuthor | controlled release | - |
dc.subject.keywordAuthor | nanocluster | - |
dc.subject.keywordPlus | POLY(ASPARTIC ACID-GRAFT-IMIDAZOLE)-BLOCK-POLY(ETHYLENE GLYCOL) | - |
dc.subject.keywordPlus | STIMULI-RESPONSIVE POLYMERS | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | SURFACE-CHEMISTRY | - |
dc.subject.keywordPlus | GOLD NANORODS | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | MICELLE | - |
dc.subject.keywordPlus | POLYELECTROLYTE | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.